Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F Colombel

Showing results (341-350 of 368) with videos related to

Pageof 37
Sort By:
Journal of Crohn'S & Colitis|December 22, 2010
European evidence-based Consensus on the management of ulcerative colitis: Current managementS P L Travis, E F Stange, M Lémann, et al.
Gastroenterologie Clinique Et Biologique|February 15, 2002
[Infliximab therapy for Crohn's disease anoperineal lesions]A Ouraghi, S Nieuviarts, J L Mougenel, et al.
Gastroenterology|March 1, 1996
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires DigestivesR Modigliani, J F Colombel, J L Dupas, et al.
Alimentary Pharmacology & Therapeutics|August 28, 2009
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodiesM Allez, S Vermeire, N Mozziconacci, et al.
Gut|February 24, 2006
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's diseaseW Reinisch, D W Hommes, G Van Assche, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2017
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitisJ-F Colombel, W J Sandborn, W Reinisch, et al.
Revista De Gastroenterologia De Mexico|March 15, 2015
[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]A Dignass, J O Lindsay, A Sturm, et al.
Inflammatory Bowel Diseases|August 23, 2001
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's diseaseW J Sandborn, E V Loftus, J F Colombel, et al.
Mucosal Immunology|October 17, 2013
Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in miceG Pineton de Chambrun, M Body-Malapel, I Frey-Wagner, et al.
European Journal of Human Genetics : EJHG|January 10, 2002
Genetic refinement and physical mapping of a chromosome 16q candidate region for inflammatory bowel diseaseH Zouali, M Chamaillard, S Lesage, et al.
Pageof 37

Showing results (341-350 of 368) with videos related to

Sort By:
Pageof 37
Journal of Crohn'S & Colitis|December 22, 2010
European evidence-based Consensus on the management of ulcerative colitis: Current managementS P L Travis, E F Stange, M Lémann, et al.
Gastroenterologie Clinique Et Biologique|February 15, 2002
[Infliximab therapy for Crohn's disease anoperineal lesions]A Ouraghi, S Nieuviarts, J L Mougenel, et al.
Gastroenterology|March 1, 1996
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires DigestivesR Modigliani, J F Colombel, J L Dupas, et al.
Alimentary Pharmacology & Therapeutics|August 28, 2009
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodiesM Allez, S Vermeire, N Mozziconacci, et al.
Gut|February 24, 2006
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's diseaseW Reinisch, D W Hommes, G Van Assche, et al.
Alimentary Pharmacology & Therapeutics|November 22, 2017
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitisJ-F Colombel, W J Sandborn, W Reinisch, et al.
Revista De Gastroenterologia De Mexico|March 15, 2015
[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management (Spanish version)]A Dignass, J O Lindsay, A Sturm, et al.
Inflammatory Bowel Diseases|August 23, 2001
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's diseaseW J Sandborn, E V Loftus, J F Colombel, et al.
Mucosal Immunology|October 17, 2013
Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in miceG Pineton de Chambrun, M Body-Malapel, I Frey-Wagner, et al.
European Journal of Human Genetics : EJHG|January 10, 2002
Genetic refinement and physical mapping of a chromosome 16q candidate region for inflammatory bowel diseaseH Zouali, M Chamaillard, S Lesage, et al.
Pageof 37